Share on StockTwits

Regulus Therapeutics (NASDAQ:RGLS) has received an average rating of “Buy” from the nine analysts that are currently covering the company, American Banking News reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $16.20.

Regulus Therapeutics (NASDAQ:RGLS) opened at 7.05 on Friday. Regulus Therapeutics has a 1-year low of $5.40 and a 1-year high of $11.88. The stock has a 50-day moving average of $7.04 and a 200-day moving average of $7.97. The company’s market cap is $305.9 million.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings data on Wednesday, August 6th. The company reported ($0.29) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.19) by $0.10. Analysts expect that Regulus Therapeutics will post $-0.89 EPS for the current fiscal year.

Separately, analysts at FBR Capital Markets raised their price target on shares of Regulus Therapeutics from $14.00 to $15.00 in a research note on Thursday, August 7th. They now have an “outperform” rating on the stock.

Regulus Therapeutics Inc, is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.